Want to join the conversation?
$ENDP said the company drove 6% underlying revenue growth in its International segment in 2015. The company expects BELBUCA to be an important growth driver going forward. On an overall basis, XIAFLEX saw 72% full year demand growth with vials totaling approx. 30,000 in 2015.
$BABA seems to be on a roll! But increasing its yearly sales outlook from 48% to 54% seems over-expectation from the company's part, doesn't it?
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?
$YHOO is reporting today after market close. Nobody cares about this stock.